{"count":3,"limit":50,"offset":0,"edits":[{"id":47015,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-48b29b62","action":"update","diff_json":{"after":0.42,"before":0.0},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":47016,"actor_id":"codex:51","entity_type":"hypothesis","entity_id":"h-48b29b62","action":"update","diff_json":{"after":"[data_support_backfill task:2ab61458-7bb9-47d8-a7f2-c17802c60840] data_support_score=0.420; evidence_component=0.18; kg_component=0.04; debate=0.10; analysis=0.10; contradiction_penalty=0.00; support_PMIDs=38713438 | kg_edges_generated=1;linked_KG=promoted-h-423b50a1,promoted-h-48b29b62 | analysis=SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04\nprior_evidence_validation={\"total_evidence\": 13, \"pmid_count\": 1, \"papers_in_db\": 1, \"description_length\": 3396, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": false, \"issues\": []}","before":"{\"total_evidence\": 13, \"pmid_count\": 1, \"papers_in_db\": 1, \"description_length\": 3396, \"has_clinical_trials\": false, \"has_pathway_diagram\": true, \"has_gene_expression\": false, \"issues\": []}"},"change_reason":"Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d8-a7f2-c17802c60840]","created_at":"2026-04-26T21:44:07.424021+00:00"},{"id":3459,"actor_id":null,"entity_type":"hypothesis","entity_id":"h-48b29b62","action":"update","diff_json":{"after":"## C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward Neurotoxic Loop\n\n### Complement Cascade and Neurotoxic Astrocyte Induction\n\nThe complement system is a central mediator of immune surveillance in the CNS, and its dysregulation has emerged as a key driver of neuroinflammation in neurodegeneration. The anaphylatoxin receptor C3aR (encoded by C3AR1) is expressed on microglia, astrocytes, and neurons, making it a pivotal node in the neuroimmune interface.\n\nThe complement cascade is initiated by pattern recognition molecules (C1q, C3) that detect damage-associated molecular patterns (DAMPs). This triggers C3a generation through proteolytic cleavage. C3a binding to C3aR activates G-protein coupled signaling (primarily Gαq), leading to PLC activation, IP3-mediated calcium release, and PKC activation. In microglia, C3aR activation drives a pro-inflammatory transcriptional program characterized by NF-κB nuclear translocation and production of IL-1β, TNF-α, and IL-6.\n\n### The A1 Astrocyte Feedback Loop\n\nA critical discovery was the identification of A1 astrocytes — a reactive astrocyte subtype induced by microglia-derived signals that is potently neurotoxic. Microglia secrete IL-1α, TNF, and C1q upon activation, and these cytokines induce A1 astrocyte formation. A1 astrocytes secrete toxic factors causing rapid death of neurons and oligodendrocytes.\n\nC3aR activation in microglia amplifies this loop at multiple points: (1) C3aR signaling enhances NF-κB activation, increasing IL-1α, TNF, and C1q production; (2) C3aR activation induces microglial proliferation and recruitment; (3) C3aR signaling increases complement component C3 production.\n\nAstrocytes themselves express C3aR, and C3a can directly activate astrocytes in a manner that reinforces their A1 phenotype. This creates a self-reinforcing feedforward loop where microglial C3aR activation → cytokine release → A1 astrocyte induction → astrocyte C3 production → additional microglial C3aR activation.\n\n### C3aR Antagonism as Therapeutic Intervention\n\nC3aR blockade interrupts this loop at a central amplification node. Unlike attempts to block individual cytokines (TNF, IL-1α), C3aR antagonism addresses the convergent amplification point. The rationale is:\n\n1. **Broad-spectrum effect:** Blocking C3aR reduces inflammatory output of microglia regardless of whether the initiating signal is Aβ, τ, α-synuclein, or trauma.\n\n2. **A1 astrocyte prevention:** By reducing microglial IL-1α/TNF/C1q secretion, C3aR blockade prevents A1 astrocyte induction.\n\n3. **Direct neuronal protection:** Neuronal C3aR activation contributes to excitotoxicity and synaptic dysfunction; C3aR blockade provides direct neuroprotection.\n\n### Small-Molecule C3aR Antagonists\n\nSeveral C3aR antagonists have been developed for inflammatory diseases. CNS-penetrant analogs with optimized logD (1.5-3.0 range) and P-gp substrate avoidance have demonstrated brain exposure in non-human primates. Allosteric modulators targeting sites on C3aR may provide selectivity over related receptors (C5aR).\n\n### Biomarker-Driven Patient Selection\n\nNot all AD patients benefit equally from C3aR blockade. Enrichment strategies include: CSF C3a levels (elevated indicates active complement amplification), CSF GFAP/YKL-40 elevation (confirms active neuroinflammation), PET TSPO positivity (in vivo microglial activation), and C3AR1 genetic variants.","before":"C3aR antagonism inhibits NF-κB-mediated A1 astrocyte induction by blocking microglial C3 secretion feedback amplification. C3aR functions as a critical 'on-switch' for the neurotoxic astrocyte program. Blocking C3aR would break this self-reinforcing loop and restore homeostatic astrocyte function."},"change_reason":null,"created_at":"2026-04-16T17:18:16+00:00"}]}